TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01690689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant surgery
Description: surgery
Study: NCT02266758

Intervention type: OTHER
Group type: OTHER
Intervention: GDM Screening Methods
Study: NCT03113448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.075% Capsaicin Lotion
Description: To apply 3-4 times per day, every day until 8 weeks then stop

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.075% Capsaicin Lotion
Description: To apply 3-4 times per day, every day until 8 weeks then stop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: To apply 3-4 times per day, every day until 8 weeks then stop

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: To apply 3-4 times per day, every day until 8 weeks then stop
Study: NCT03613116

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D
Study: NCT00906113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial injection of melphalan
Description: Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of melphalan into the ophthalmic artery
Description: Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
Study: NCT01949948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: 0.4 mg/kg single bolus intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: 0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
Study: NCT00054041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HspE7
Description: Given subcutaneously

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo large loop excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo large loop excision

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04212533

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: comparison between pre- and postoperative calcium and vitamin d level after vit d and calcium supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: rice starch tablets
Description: rice starch tablets as placebo
Study: NCT03533257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMX0035
Description: Combination Therapy of TUDCA and Sodium Phenylbutyrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02944942

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Patients undergoing general anesthesia
Study: NCT02689245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Study: NCT04294420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education program
Description: The education program provides information and guidance concerning aetiology, diagnostics and treatment of pain-predominant functional gastrointestinal disorders. The patient education program will be provided in a group setting and the children will participate along with one of their parents. The participants (n=20) will be divided into two groups consisting of ten child-parent pairs. Two lectures will be held, two weeks apart, two hours per lecture. Represented teachers are physician, psychologist and dietician.
Study: NCT03597360

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Participants will receive the first LDIR treatment in one session on the same day, i.e., two CT scans of the brain that delivers a total X-ray dose (CTDIvol)10 of about 80 mGy. Participants will then be transported back to Baycrest Health Sciences. Participants will receive another LDIR treatment, i.e. a single CT scan of the brain (40 mGy), 2 weeks after the first session. They will receive a third LDIR treatment, i.e., a single CT scan of the brain (40 mGy), 2 weeks after the second session. Date, time and X-ray dose will be recorded for each participant and sent to their family physician for entry into in their health record.
Study: NCT03236142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIPS Operation
Description: The SIPS modification of the DS operation entails one less division of the small intestine and one less anastomosis, thereby reducing the time of the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Duodenal Switch Operation
Study: NCT03754751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy with the implementation of modified ERAS program
Description: Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient informing and brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Low-pressure pneumoperitoneum (8-9 mmHg)~2. Trocar wound and intraabdominal anesthesia with 0.25% ropivacaine~3. PONV prophylaxis in patients of risk~Postoperative care~1. Early mobilization (2 h after surgery)~2. Early fluid intake (2 h after surgery)~3. Early liquid food (6 h after surgery) Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy with standard perioperative treatment
Description: Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient oral informing. No brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Standard CO2 pressure (12-14 mmHg)~2. No additional anesthesia~Postoperative care~1. Mobilization in 4-6 h after surgery~2. Fluid intake in 6 hours~3. Liquid food intake in 12 hours Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery
Study: NCT02872363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention A - Behavioural Regulation
Description: SMS reminder with 'Behavioural Regulation' message:~'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention B - Priority
Description: SMS reminder with 'Priority' message:~'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'
Study: NCT02733952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericervical Tourniquet
Study: NCT03898921

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Description: RFA with a safe margin, RFA again if residual,no more than 3 times.
Study: NCT04135196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: voluntary forearm loading task
Description: voluntary task, consisting of leaning onto the palm of the hand until a target force is reached. Each loading bout consists of 100 loading cycles, which takes approximately 2 minutes to complete. The task is performed 4 times per week during the intervention period.
Study: NCT00853918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $20 cash
Description: $20 cash incentive mailed with survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $50 cash
Description: $50 cash incentive mailed with survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $50 check
Description: $50 check incentive mailed with survey
Study: NCT00853918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $100 check
Description: $100 check incentive mailed with survey
Study: NCT02639091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 94-9343
Description: In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).~In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)
Study: NCT04135196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: voluntary forearm loading task
Description: voluntary task, consisting of leaning onto the palm of the hand until a target force is reached. Each loading bout consists of 100 loading cycles, which takes approximately 2 minutes to complete. The task is performed 4 times per week during the intervention period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: voluntary forearm loading task
Description: voluntary task, consisting of leaning onto the palm of the hand until a target force is reached. Each loading bout consists of 100 loading cycles, which takes approximately 2 minutes to complete. The task is performed 4 times per week during the intervention period.
Study: NCT02639091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
Study: NCT01599104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Olmesartan 20 mg capsule one daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to LCZ696 or Olmesartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to LCZ696 or Olmesartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to LCZ696 or Olmesartan
Study: NCT04479865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 5mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 5mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 5mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 5mg Tablet
Description: 1 tablet once daily
Study: NCT02880020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04479865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 10mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 10mg Tablet
Description: 1 tablet once daily
Study: NCT01179126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: complete multivessel revascularization
Description: After a successful primary PCI these patients will undergo complete revascularization of non-culprit lesions in a staged procedure during the index admission

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stress echocardiography and revascularization if required
Description: after successful primary PCI, this group will undergo a stress echo to evaluate the significance of non-culprit lesions. If large area of ischemia is demonstrated, the artery supplying that are will be revascularized.
Study: NCT03140995

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking Programme
Description: The programme will be devised using incremental targets for daily walks based on the 6-20 Borg of rating of perceived exertion scale (Borg RPE). They will be instructed that they should be moderately short of breath on exertion i.e. unable to comfortably hold a conversation while walking
Study: NCT04479865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 10mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 10mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207 150mg
Description: 1 patch once weekly
Study: NCT02881164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index
Description: Subjects intake a low glycemic index breakfast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High glycemic index
Description: Subjects intake a high glycemic index breakfast
Study: NCT02379286

Intervention type: OTHER
Intervention: Investigation
Description: Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
Study: NCT02003911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin suspension (200mg/5mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04479865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207 150mg
Description: 1 patch once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207 170mg
Description: 1 patch once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207 170mg
Description: 1 patch once weekly
Study: NCT06224946

Intervention type: DIAGNOSTIC_TEST
Intervention: soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio
Description: the soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio for pre-eclampsia diagnostic
Study: NCT02199340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iStep exercise test
Description: newly developed submaximal exercise test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iStep exercise test
Description: newly developed submaximal exercise test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPET exercise test
Description: maximal gold standard exercise test
Study: NCT02148679

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DASH/SRD
Description: Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH/SRD
Description: Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Standardized advice to restrict dietary sodium intake to \< 2000 mg/day
Study: NCT00794976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Iontophoretic Patch (low dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Iontophoretic Patch (high dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Passive Patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Study: NCT02599259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitored (M+)
Description: Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
Study: NCT03486054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTERCEPT
Description: The pathogen reduction process begins with a unit of whole blood collected according to local standards and procedures at the blood center. The blood unit is treated with amustaline and glutathione (INTERCEPT blood system for whole blood) according to manufacturer's instructions. The INTERCEPT blood system is performed on a single unit of not leuco-reduced whole blood treated with amustaline and glutathione in CPD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The control article is Standard of Care, either RBC or whole blood collected by the Centre National de Transfusion Sanguine (CNTS), processed according to the local procedure and in compliance with quality criteria defined by the manufacture regarding the volume, hemoglobin content, hematocrit, storage temperature, age of blood and storage in the predefined anticoagulant solution.
Study: NCT02697773

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Description: Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5mg/5mg
Description: Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
Study: NCT01138111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetaben (BAY94-9172)
Description: single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
Study: NCT04576182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive-expressive treatment
Description: Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotions-Focused treatment
Description: Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.
Study: NCT04764955

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This product is identical in appearance, taste and texture to the experimental formulation but does not include any vitamin D3.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This product is identical in appearance, taste and texture to the experimental formulation but does not include any vitamin D3.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This product is identical in appearance, taste and texture to the experimental formulation but does not include any vitamin D3.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This product is identical in appearance, taste and texture to the experimental formulation but does not include any vitamin D3.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: The intervention is an oral tablet containing vitamin D3 (cholecalciferol). Each weekly dose consists of a single tablet. Vitamin D3 content of the dose depends on the intervention group.
Study: NCT03047850

Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of Delta Down and Delta Pulse Pressure
Description: Comparison of Delta Down and Delta Pulse Pressure Before and After Sternotomy.